| Company Name: | AstraZeneca PLC | | Ticker Symbol: | AZN | | | WWW Address: | www.astrazeneca.com |
| CEO: | Pascal Soriot | | No. of Employees: | 51,700 |
| Common Issue Type: | AD | | Business Description: | AstraZeneca PLC a biopharmaceutical company focusing on six Therapy Areas: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology and Respiratory & Inflammation. It owns and operates R&D, production and marketing facilities worldwide.
|
| | | Industry Information: | DRUGS - Drug Manufacturers - Major [more like this] |
| | Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 52.08 |  -0.27 | - | - | 51.91 | 52.72 | 51.94 | 1637097 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 65,100.0 | 1,250.0 | 0.62 | 4.98 | 2.85 | 11.6 | 7.3 | 52.72 - 39.72 |
| | KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 52.35 | $ | | PE Ratio - LTM | 11.6 | |
| Market Capitalisation | 65,100.0 | mil |
| Latest Shares Outstanding | 1,250.0 | mil |
| Earnings pS (EPS) | 4.98 | $ |
| Dividend pS (DPS) | 2.85 | ¢ |
| Dividend Yield | 7.3 | % |
| Dividend Payout Ratio | 57 | % |
| Revenue per Employee | 541,064 | $ |
| Effective Tax Rate | 18.0 | % |
| Float | 0.0 | mil |
| Float as % of Shares Outstanding | 0.0 | % |
| Foreign Sales | 33,620 | mil |
| Domestic Sales | 8,782 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 37.80 | % |
| Research & Devlopment (R&D) as % of Revenue | 18.40 | % |
| Gross Profit Margin | 90.3 | % |
| EBITDA Margin | 34.1 | % |
| Pre-Tax Profit Margin | 25.8 | % |
| Assets Turnover | 0.5 | % |
| Return on Assets (ROA) | 7.8 | % |
| Return on Equity (ROE) | 18.3 | % |
| Return on Capital Invested (ROCI) | 12.9 | % |
| Current Ratio | 1.3 | |
| Leverage Ratio (Assets/Equity) | 2.3 | |
| Interest Cover | 5.5 | |
| Total Debt/Equity (Gearing Ratio) | 0.46 | |
| LT Debt/Total Capital | 29.0 | % |
| Working Capital pS | 3.59 | $ |
| Cash pS | 5.79 | $ |
| Book-Value pS | 17.83 | $ |
| Tangible Book-Value pS | -2.91 | $ |
| Cash Flow pS | 5.40 | $ |
| Free Cash Flow pS | -1.49 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 2.94 | |
| Price/Tangible Book Ratio | -17.98 | |
| Price/Cash Flow | 9.7 | |
| Price/Free Cash Flow | -35.0 | |
| P/E as % of Industry Group | 44.0 | % |
| P/E as % of Sector Segment | 62.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Dividend Declared Date | 01/30/2013 |
| Dividend Ex-Date | 02/12/2013 |
| Dividend Record Date | 02/14/2013 |
| Dividend Pay Date | 03/17/2013 |
| Dividend Amount | 1900 |
| Type of Payment | Cash Payment |
| Dividend Rate | 3.80 |
| Current Dividend Yield | 7.3 |
| 5-Y Average Dividend Yield | 3.1 |
| Payout Ratio | 57.0 |
| 5-Y Average Payout Ratio | 45.0 |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | | | | | PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 1.5 | 102 | 19,535 | 77,828 |
| 4 Weeks | 52.72 | 50.92 | 51.55 | 1.6 | 97 | 16,614 | 299,048 |
| 13 Weeks | 52.72 | 44.62 | 45.18 | 15.9 | 106 | 20,488 | 1,270,240 |
| 26 Weeks | 52.72 | 44.46 | 46.46 | 12.7 | 96 | 17,946 | 2,207,375 |
| 52 Weeks | 52.72 | 39.72 | 41.23 | 27.0 | 101 | 16,020 | 3,956,837 |
| YTD | 52.72 | 44.46 | - | 10.7 | 95 | 19,632 | 1,923,909 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 51.79 | 51.64 | 50.69 | 48.27 | 47.93 | 0.62 | 0.55 |
| | | | GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | -1.34 | 11.4 | -5.87 |
| Income | 7.13 | 35.2 | -3.43 |
| Dividend | 9.48 | 94.8 | 6.90 |
| Capital Spending | 0.00 | NA | 0.00 |
| R&D | 1.13 | NA | 3.54 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | -13.1 | -13.1 | -16.7 |
| Earnings % | -38.4 | -38.4 | 0.0 |
| EPS % | -36.7 | -36.7 | -31.8 |
| EPS $ | -0.47 | -0.47 | -2.32 |
| | | | SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 9.61 |
| Current Ratio | 1.4 |
| Quick Ratio (Acid Test) | 1.2 |
| Liquidity Ratio (Cash) | 0.61 |
| Receivables Turnover | 3.1 |
| Average Collection Period | 116 |
| Working Capital/Equity | 21.7 |
| Working Capital pS | 4.13 |
| Cash-Flow pS | 7.09 |
| Free Cash-Flow pS | -2.02 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 2.73 |
| Financial Leverage Ratio (Assets/Equity) | 2.3 |
| Debt Ratio | 55.7 |
| Total Debt/Equity (Gearing Ratio) | 0.43 |
| LT Debt/Equity | 0.40 |
| LT Debt/Capital Invested | 48.0 |
| LT Debt/Total Liabilities | 31.6 |
| Interest Cover | 9.1 |
| Interest/Capital Invested | 2.42 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 11.70 |
| Tobin's Q Ratio | 1.22 |
| Current P/E Ratio - LTM | 11.60 |
| Enterprise Value (EV)/EBITDA | 8.94 |
| Enterprise Value (EV)/Free Cash Flow | -33.65 |
| Dividend Yield | 7.3 |
| Price/Tangible Book Ratio - LTM | -17.98 |
| Price/Book Ratio - LTM | 2.94 |
| Price/Cash Flow Ratio | 9.7 |
| Price/Free Cash Flow Ratio - LTM | -35.0 |
| Price/Sales Ratio | 2.42 |
| P/E Ratio (1 month ago) - LTM | 11.4 |
| P/E Ratio (26 weeks ago) - LTM | 9.4 |
| P/E Ratio (52 weeks ago) - LTM | 6.3 |
| 5-Y High P/E Ratio | 11.9 |
| 5-Y Low P/E Ratio | 5.6 |
| 5-Y Average P/E Ratio | 8.6 |
| Current P/E Ratio as % of 5-Y Average P/E | 135 |
| P/E as % of Industry Group | 44.0 |
| P/E as % of Sector Segment | 62.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 10.8 |
| PER SHARE FIGURES |
| LT Debt pS | 7.55 |
| Current Liabilities pS | 11.15 |
| Tangible Book Value pS - LTM | -2.91 |
| Book Value pS - LTM | 17.83 |
| Capital Invested pS | 26.52 |
| Cash pS - LTM | 5.79 |
| Cash Flow pS - LTM | 5.40 |
| Free Cash Flow pS - LTM | -1.49 |
| Earnings pS (EPS) | 4.98 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -9.02 |
| Free Cash Flow Margin 5YEAR AVG | 8.56 |
| Net Profit Margin | 22.6 |
| Net Profit Margin - 5YEAR AVRG. | 7.8 |
| Equity Productivity | 1.18 |
| Return on Equity (ROE) | 26.7 |
| Return on Equity (ROE) - 5YEAR AVRG. | 11.6 |
| Capital Invested Productivity | 0.84 |
| Return on Capital Invested (ROCI) | 19.1 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 8.6 |
| Assets Productivity | 0.50 |
| Return on Assets (ROA) | 11.8 |
| Return on Assets (ROA) - 5YEAR AVRG. | 4.7 |
| Gross Profit Margin | 90.3 |
| Gross Profit Margin - 5YEAR AVRG. | 88.9 |
| EBITDA Margin - LTM | 34.1 |
| EBIT Margin - LTM | 30.2 |
| Pre-Tax Profit Margin | 27.6 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 31.7 |
| Effective Tax Rate | 18.0 |
| Effective Tax Rate - 5YEAR AVRG. | 24.6 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 354 |
| Revenue per Employee | 541,064 |
| Net Income per Employee | 122,379 |
| Average Collection Period | 109 |
| Receivables Turnover | 3.1 |
| Day's Inventory Turnover Ratio | 245 |
| Inventory Turnover | 1.5 |
| Inventory/Sales | 7.4 |
| Accounts Payble/Sales | 32.96 |
| Assets/Revenue | 2.00 |
| Net Working Capital Turnover | 5.44 |
| Fixed Assets Turnover | 0.81 |
| Total Assets Turnover | 0.5 |
| Revenue per $ Cash | 3.63 |
| Revenue per $ Plant | 4.59 |
| Revenue per $ Common Equity | 1.18 |
| Revenue per $ Capital Invested | 0.84 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 36.3 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 34.7 |
| Research & Devlopment (R&D) as % of Revenue | 18.7 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 18.7 |
|
|  
| | |  |  | |
| |
